These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
o
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
Delaware
|
|
51-0014090
|
|
(State or other Jurisdiction of
|
|
(I.R.S. Employer
|
|
Incorporation or Organization)
|
|
Identification No.)
|
|
Large Accelerated Filer
x
|
|
Accelerated Filer
o
|
|
|
|
|
|
Non-Accelerated Filer
o
|
|
Smaller reporting company
o
|
|
|
|
|
|
Page
|
|
|
|
|||
|
|
|
|
|
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|
||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|
|
|
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|||
|
|
|||
|
|
|||
|
Item 1.
|
CONSOLIDATED FINANCIAL STATEMENTS
|
|
|
Three Months Ended
|
|
Nine Months Ended
|
||||||||||||
|
|
September 30,
|
|
September 30,
|
||||||||||||
|
|
2011
|
|
2010
|
|
2011
|
|
2010
|
||||||||
|
Net sales
|
$
|
9,238
|
|
|
$
|
7,001
|
|
|
$
|
29,536
|
|
|
$
|
24,101
|
|
|
Other income, net
|
161
|
|
|
66
|
|
|
415
|
|
|
890
|
|
||||
|
Total
|
9,399
|
|
|
7,067
|
|
|
29,951
|
|
|
24,991
|
|
||||
|
|
|
|
|
|
|
|
|
||||||||
|
Cost of goods sold and other operating charges
|
7,107
|
|
|
5,443
|
|
|
21,129
|
|
|
17,223
|
|
||||
|
Selling, general and administrative expenses
|
1,014
|
|
|
782
|
|
|
3,177
|
|
|
2,796
|
|
||||
|
Research and development expense
|
557
|
|
|
409
|
|
|
1,418
|
|
|
1,178
|
|
||||
|
Interest expense
|
116
|
|
|
103
|
|
|
331
|
|
|
309
|
|
||||
|
Employee separation / asset related charges, net
|
36
|
|
|
—
|
|
|
36
|
|
|
—
|
|
||||
|
Total
|
8,830
|
|
|
6,737
|
|
|
26,091
|
|
|
21,506
|
|
||||
|
|
|
|
|
|
|
|
|
||||||||
|
Income before income taxes
|
569
|
|
|
330
|
|
|
3,860
|
|
|
3,485
|
|
||||
|
Provision for (benefit from) income taxes
|
109
|
|
|
(39
|
)
|
|
727
|
|
|
811
|
|
||||
|
Net income
|
460
|
|
|
369
|
|
|
3,133
|
|
|
2,674
|
|
||||
|
Less: Net income attributable to noncontrolling interests
|
8
|
|
|
2
|
|
|
32
|
|
|
19
|
|
||||
|
Net income attributable to DuPont
|
$
|
452
|
|
|
$
|
367
|
|
|
$
|
3,101
|
|
|
$
|
2,655
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Basic earnings per share of common stock
|
$
|
0.48
|
|
|
$
|
0.40
|
|
|
$
|
3.33
|
|
|
$
|
2.92
|
|
|
Diluted earnings per share of common stock
|
$
|
0.48
|
|
|
$
|
0.40
|
|
|
$
|
3.28
|
|
|
$
|
2.89
|
|
|
Dividends per share of common stock
|
$
|
0.41
|
|
|
$
|
0.41
|
|
|
$
|
1.23
|
|
|
$
|
1.23
|
|
|
|
September 30,
2011 |
|
December 31,
2010 |
||||
|
Assets
|
|
|
|
|
|
||
|
Current assets
|
|
|
|
|
|
||
|
Cash and cash equivalents
|
$
|
2,750
|
|
|
$
|
4,263
|
|
|
Marketable securities
|
229
|
|
|
2,538
|
|
||
|
Accounts and notes receivable, net
|
8,544
|
|
|
5,635
|
|
||
|
Inventories
|
6,413
|
|
|
5,967
|
|
||
|
Prepaid expenses
|
154
|
|
|
122
|
|
||
|
Deferred income taxes
|
705
|
|
|
534
|
|
||
|
Total current assets
|
18,795
|
|
|
19,059
|
|
||
|
Property, plant and equipment, net of accumulated depreciation
(September 30, 2011 - $19,362; December 31, 2010 - $18,628)
|
13,235
|
|
|
11,339
|
|
||
|
Goodwill
|
5,493
|
|
|
2,617
|
|
||
|
Other intangible assets
|
5,550
|
|
|
2,704
|
|
||
|
Investment in affiliates
|
1,079
|
|
|
1,041
|
|
||
|
Other assets
|
3,642
|
|
|
3,650
|
|
||
|
Total
|
$
|
47,794
|
|
|
$
|
40,410
|
|
|
|
|
|
|
||||
|
Liabilities and Stockholders’ Equity
|
|
|
|
|
|
||
|
Current liabilities
|
|
|
|
|
|
||
|
Accounts payable
|
$
|
3,981
|
|
|
$
|
4,230
|
|
|
Short-term borrowings and capital lease obligations
|
3,301
|
|
|
133
|
|
||
|
Income taxes
|
520
|
|
|
225
|
|
||
|
Other accrued liabilities
|
3,568
|
|
|
4,801
|
|
||
|
Total current liabilities
|
11,370
|
|
|
9,389
|
|
||
|
Long-term borrowings and capital lease obligations
|
12,200
|
|
|
10,137
|
|
||
|
Other liabilities
|
11,065
|
|
|
11,026
|
|
||
|
Deferred income taxes
|
1,135
|
|
|
115
|
|
||
|
Total liabilities
|
35,770
|
|
|
30,667
|
|
||
|
|
|
|
|
||||
|
Commitments and contingent liabilities
|
|
|
|
|
|
||
|
|
|
|
|
||||
|
Stockholders’ equity
|
|
|
|
|
|
||
|
Preferred stock
|
237
|
|
|
237
|
|
||
|
Common stock, $0.30 par value; 1,800,000,000 shares authorized;
Issued at September 30, 2011 - 1,010,894,000; December 31, 2010 - 1,004,351,000
|
303
|
|
|
301
|
|
||
|
Additional paid-in capital
|
9,983
|
|
|
9,227
|
|
||
|
Reinvested earnings
|
13,432
|
|
|
12,030
|
|
||
|
Accumulated other comprehensive loss
|
(5,684
|
)
|
|
(5,790
|
)
|
||
|
Common stock held in treasury, at cost (87,041,000
shares at September 30, 2011 and December 31, 2010)
|
(6,727
|
)
|
|
(6,727
|
)
|
||
|
Total DuPont stockholders’ equity
|
11,544
|
|
|
9,278
|
|
||
|
Noncontrolling interests
|
480
|
|
|
465
|
|
||
|
Total equity
|
12,024
|
|
|
9,743
|
|
||
|
Total
|
$
|
47,794
|
|
|
$
|
40,410
|
|
|
|
Nine Months Ended
|
||||||
|
|
September 30,
|
||||||
|
|
2011
|
|
2010
|
||||
|
Operating activities
|
|
|
|
|
|
||
|
Net income
|
$
|
3,133
|
|
|
$
|
2,674
|
|
|
Adjustments to reconcile net income to cash provided by operating activities:
|
|
|
|
|
|
||
|
Depreciation
|
944
|
|
|
904
|
|
||
|
Amortization of intangible assets
|
195
|
|
|
142
|
|
||
|
Contributions to pension plans
|
(272
|
)
|
|
(704
|
)
|
||
|
Other noncash charges and credits - net
|
846
|
|
|
442
|
|
||
|
Change in operating assets and liabilities - net
|
(4,415
|
)
|
|
(3,423
|
)
|
||
|
Cash provided by operating activities
|
431
|
|
|
35
|
|
||
|
|
|
|
|
||||
|
Investing activities
|
|
|
|
|
|
||
|
Purchases of property, plant and equipment
|
(1,211
|
)
|
|
(899
|
)
|
||
|
Investments in affiliates
|
(35
|
)
|
|
(71
|
)
|
||
|
Payments for businesses - net of cash acquired
|
(6,459
|
)
|
|
—
|
|
||
|
Proceeds from sales of assets - net of cash sold
|
62
|
|
|
173
|
|
||
|
Net decrease in short-term financial instruments
|
2,365
|
|
|
201
|
|
||
|
Forward exchange contract settlements
|
(299
|
)
|
|
396
|
|
||
|
Other investing activities - net
|
1
|
|
|
(94
|
)
|
||
|
Cash used for investing activities
|
(5,576
|
)
|
|
(294
|
)
|
||
|
|
|
|
|
||||
|
Financing activities
|
|
|
|
|
|
||
|
Dividends paid to stockholders
|
(1,152
|
)
|
|
(1,122
|
)
|
||
|
Net increase in borrowings
|
4,503
|
|
|
1,327
|
|
||
|
Repurchase of common stock
|
(672
|
)
|
|
—
|
|
||
|
Proceeds from exercise of stock options
|
833
|
|
|
199
|
|
||
|
Other financing activities - net
|
52
|
|
|
(18
|
)
|
||
|
Cash provided by financing activities
|
3,564
|
|
|
386
|
|
||
|
Effect of exchange rate changes on cash
|
68
|
|
|
(60
|
)
|
||
|
(Decrease) increase in cash and cash equivalents
|
$
|
(1,513
|
)
|
|
$
|
67
|
|
|
Cash and cash equivalents at beginning of period
|
4,263
|
|
|
4,021
|
|
||
|
Cash and cash equivalents at end of period
|
$
|
2,750
|
|
|
$
|
4,088
|
|
|
|
Pro forma for the
Three Months Ended
September 30,
|
|
Pro forma for the
Nine Months Ended
September 30,
|
||||||||||||
|
|
2011
|
|
2010
|
|
2011
|
|
2010
|
||||||||
|
Net sales
|
$
|
9,238
|
|
|
$
|
7,678
|
|
|
$
|
30,757
|
|
|
$
|
26,110
|
|
|
Net income attributable to DuPont
|
544
|
|
|
400
|
|
|
3,344
|
|
|
2,531
|
|
||||
|
Fair value of assets acquired
|
|
||
|
Cash and cash equivalents
|
$
|
48
|
|
|
Accounts and notes receivable
1
|
522
|
|
|
|
Inventories
2
|
709
|
|
|
|
Property, plant and equipment
|
1,720
|
|
|
|
Goodwill
3
|
2,900
|
|
|
|
Other intangible assets
4
|
2,859
|
|
|
|
Other current and non-current assets
|
79
|
|
|
|
Total assets acquired
|
$
|
8,837
|
|
|
|
|
||
|
Fair value of liabilities assumed
|
|
||
|
Accounts payable and other accrued liabilities
|
$
|
482
|
|
|
Short-term borrowings
|
342
|
|
|
|
Long-term borrowings
|
323
|
|
|
|
Other liabilities
|
219
|
|
|
|
Deferred income taxes
5
|
1,054
|
|
|
|
Total liabilities assumed
|
$
|
2,420
|
|
|
1
|
The gross amount of accounts and notes receivable acquired was
$531
, of which
$9
was expected to be uncollectible.
|
|
2
|
The fair value of inventories acquired included a step-up in the value of
$175
, of which
$132
and
$175
was expensed to cost of goods sold and other operating charges for the three and nine month periods ended September 30, 2011, respectively.
|
|
3
|
Goodwill will not be deductible for statutory tax purposes. Goodwill is attributable to Danisco's workforce and the synergies in technology, operations and market access that are expected from the acquisition. Approximately
$900
and
$2,000
of goodwill was allocated to the Industrial Biosciences and Nutrition & Health segments, respectively.
|
|
4
|
Other intangible assets acquired of
$1,002
are indefinite-lived (see Note 9).
|
|
5
|
The deferred income tax liabilities assumed represent the adjustments for the tax impact of fair value adjustments, primarily relating to definite-lived intangible assets.
|
|
|
Three Months Ended
|
|
Nine Months Ended
|
||||||||||||
|
|
September 30,
|
|
September 30,
|
||||||||||||
|
|
2011
|
|
2010
|
|
2011
|
|
2010
|
||||||||
|
Cozaar
®
/Hyzaar
®
income
|
$
|
68
|
|
|
$
|
109
|
|
|
$
|
195
|
|
|
$
|
397
|
|
|
Royalty income
|
30
|
|
|
36
|
|
|
96
|
|
|
89
|
|
||||
|
Interest income
|
28
|
|
|
28
|
|
|
88
|
|
|
68
|
|
||||
|
Equity in earnings of affiliates, excluding
exchange gains/losses
|
34
|
|
|
33
|
|
|
117
|
|
|
119
|
|
||||
|
Net (losses) gains on sales of assets
|
(1
|
)
|
|
1
|
|
|
38
|
|
|
96
|
|
||||
|
Net exchange losses
1
|
(6
|
)
|
|
(160
|
)
|
|
(145
|
)
|
|
(25
|
)
|
||||
|
Miscellaneous income and expenses, net
2
|
8
|
|
|
19
|
|
|
26
|
|
|
146
|
|
||||
|
Total
|
$
|
161
|
|
|
$
|
66
|
|
|
$
|
415
|
|
|
$
|
890
|
|
|
|
Employee
Separation
Costs
|
||
|
Charges to income for three and nine months ended September 30, 2011
|
$
|
36
|
|
|
Payments
|
(1
|
)
|
|
|
Balance as of September 30, 2011
|
$
|
35
|
|
|
|
Employee
Separation
Costs
|
|
Other Non-
personnel
Charges
1
|
|
Total
|
||||||
|
Balance at December 31, 2010
|
$
|
46
|
|
|
$
|
1
|
|
|
$
|
47
|
|
|
Payments
|
(36
|
)
|
|
(1
|
)
|
|
(37
|
)
|
|||
|
Net translation adjustment
|
2
|
|
|
—
|
|
|
2
|
|
|||
|
Balance as of September 30, 2011
|
$
|
12
|
|
|
$
|
—
|
|
|
$
|
12
|
|
|
1
|
Other non-personnel charges consist of contractual obligation costs.
|
|
|
Three Months Ended
|
|
Nine Months Ended
|
||||||||||||
|
|
September 30,
|
|
September 30,
|
||||||||||||
|
|
2011
|
|
2010
|
|
2011
|
|
2010
|
||||||||
|
Numerator:
|
|
|
|
|
|
|
|
|
|
||||||
|
Net income attributable to DuPont
|
$
|
452
|
|
|
$
|
367
|
|
|
$
|
3,101
|
|
|
$
|
2,655
|
|
|
Preferred dividends
|
(3
|
)
|
|
(3
|
)
|
|
(8
|
)
|
|
(8
|
)
|
||||
|
Net income available to DuPont common stockholders
|
$
|
449
|
|
|
$
|
364
|
|
|
$
|
3,093
|
|
|
$
|
2,647
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Denominator:
|
|
|
|
|
|
|
|
|
|
||||||
|
Weighted-average number of common shares - Basic
|
932,356,000
|
|
|
908,366,000
|
|
|
929,369,000
|
|
|
906,991,000
|
|
||||
|
Dilutive effect of the company’s employee
compensation plans
|
11,129,000
|
|
|
10,134,000
|
|
|
13,443,000
|
|
|
7,996,000
|
|
||||
|
Weighted-average number of common shares - Diluted
|
943,485,000
|
|
|
918,500,000
|
|
|
942,812,000
|
|
|
914,987,000
|
|
||||
|
|
Three Months Ended
|
|
Nine Months Ended
|
||||||||
|
|
September 30,
|
|
September 30,
|
||||||||
|
|
2011
|
|
2010
|
|
2011
|
|
2010
|
||||
|
Average number of stock options
|
8,678,000
|
|
|
47,108,000
|
|
|
2,904,000
|
|
|
56,845,000
|
|
|
Level 1 —
|
Quoted market prices in active markets for identical assets or liabilities;
|
|
|
|
|
Level 2 —
|
Significant other observable inputs (e.g. quoted prices for similar items in active markets, quoted prices for identical or similar items in markets that are not active, inputs other than quoted prices that are observable such as interest rate and yield curves, and market-corroborated inputs);
|
|
|
|
|
Level 3 —
|
Unobservable inputs for the asset or liability, which are valued based on management’s estimates of assumptions that market participants would use in pricing the asset or liability.
|
|
|
|
|
Fair Value Measurements at
September 30, 2011 Using
|
||||||||
|
|
September 30, 2011
|
|
Level 1 Inputs
|
|
Level 2 Inputs
|
||||||
|
Financial assets
|
|
|
|
|
|
|
|
|
|||
|
Derivatives
|
$
|
301
|
|
|
$
|
—
|
|
|
$
|
301
|
|
|
Available-for-sale securities
|
11
|
|
|
11
|
|
|
—
|
|
|||
|
|
$
|
312
|
|
|
$
|
11
|
|
|
$
|
301
|
|
|
|
|
|
|
|
|
||||||
|
Financial liabilities
|
|
|
|
|
|
|
|
|
|||
|
Derivatives
|
$
|
101
|
|
|
$
|
—
|
|
|
$
|
101
|
|
|
|
|
|
Fair Value Measurements at December 31, 2010 Using
|
||||||||
|
|
December 31, 2010
|
|
Level 1 Inputs
|
|
Level 2 Inputs
|
||||||
|
Financial assets
|
|
|
|
|
|
|
|
|
|||
|
Derivatives
|
$
|
153
|
|
|
$
|
—
|
|
|
$
|
153
|
|
|
Available-for-sale securities
|
17
|
|
|
17
|
|
|
—
|
|
|||
|
|
$
|
170
|
|
|
$
|
17
|
|
|
$
|
153
|
|
|
|
|
|
|
|
|
||||||
|
Financial liabilities
|
|
|
|
|
|
|
|
|
|||
|
Derivatives
|
$
|
132
|
|
|
$
|
—
|
|
|
$
|
132
|
|
|
|
September 30,
2011 |
|
December 31,
2010 |
||||
|
Finished products
|
$
|
3,773
|
|
|
$
|
3,191
|
|
|
Semifinished products
|
2,368
|
|
|
2,564
|
|
||
|
Raw materials, stores and supplies
|
1,099
|
|
|
855
|
|
||
|
|
7,240
|
|
|
6,610
|
|
||
|
Adjustment of inventories to a last-in, first-out (LIFO) basis
|
(827
|
)
|
|
(643
|
)
|
||
|
Total
|
$
|
6,413
|
|
|
$
|
5,967
|
|
|
|
September 30, 2011
|
|
December 31, 2010
|
||||||||||||||||||||
|
|
Gross
|
|
Accumulated
Amortization
|
|
Net
|
|
Gross
|
|
Accumulated
Amortization
|
|
Net
|
||||||||||||
|
Intangible assets subject to amortization
(Definite-lived):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
Customer lists
|
$
|
1,927
|
|
|
$
|
(219
|
)
|
|
$
|
1,708
|
|
|
$
|
525
|
|
|
$
|
(160
|
)
|
|
$
|
365
|
|
|
Patents
|
529
|
|
|
(65
|
)
|
|
464
|
|
|
118
|
|
|
(44
|
)
|
|
74
|
|
||||||
|
Purchased and licensed technology
|
1,815
|
|
|
(859
|
)
|
|
956
|
|
|
1,617
|
|
|
(765
|
)
|
|
852
|
|
||||||
|
Trademarks
|
57
|
|
|
(24
|
)
|
|
33
|
|
|
57
|
|
|
(22
|
)
|
|
35
|
|
||||||
|
Other
1
|
377
|
|
|
(183
|
)
|
|
194
|
|
|
333
|
|
|
(163
|
)
|
|
170
|
|
||||||
|
|
4,705
|
|
|
(1,350
|
)
|
|
3,355
|
|
|
2,650
|
|
|
(1,154
|
)
|
|
1,496
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
Intangible assets not subject to
amortization (Indefinite-lived):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
In-process research and development
|
71
|
|
|
—
|
|
|
71
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||
|
Microbial cell factories
2
|
306
|
|
|
—
|
|
|
306
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||
|
Pioneer germplasm
3
|
975
|
|
|
—
|
|
|
975
|
|
|
975
|
|
|
—
|
|
|
975
|
|
||||||
|
Trademarks/tradenames
|
843
|
|
|
—
|
|
|
843
|
|
|
233
|
|
|
—
|
|
|
233
|
|
||||||
|
|
2,195
|
|
|
—
|
|
|
2,195
|
|
|
1,208
|
|
|
—
|
|
|
1,208
|
|
||||||
|
Total
|
$
|
6,900
|
|
|
$
|
(1,350
|
)
|
|
$
|
5,550
|
|
|
$
|
3,858
|
|
|
$
|
(1,154
|
)
|
|
$
|
2,704
|
|
|
1
|
Primarily consists of sales and grower networks, marketing and manufacturing alliances and noncompetition agreements.
|
|
2
|
Microbial cell factories, derived from natural microbes, are used to sustainably produce enzymes, peptides and chemicals using natural metabolic processes. The company recognized the microbial cell factories as an intangible asset upon the acquisition of Danisco. This intangible asset is expected to contribute to cash flows beyond the foreseeable future and there are no legal, regulatory, contractual, or other factors which limit its useful life.
|
|
3
|
Pioneer germplasm is the pool of genetic source material and body of knowledge gained from the development and delivery stage of plant breeding. The company recognized germplasm as an intangible asset upon the acquisition of Pioneer. This intangible asset is expected to contribute to cash flows beyond the foreseeable future and there are no legal, regulatory, contractual, or other factors which limit its useful life.
|
|
|
Short-Term
|
|
Long-Term
|
|
Total
|
||||||
|
Obligations for customers and suppliers
1
:
|
|
|
|
|
|
|
|
|
|||
|
Bank borrowings (terms up to 5 years)
|
$
|
142
|
|
|
$
|
170
|
|
|
$
|
312
|
|
|
Leases on equipment and facilities (terms up to 4 years)
|
—
|
|
|
1
|
|
|
1
|
|
|||
|
Obligations for other affiliated companies
2
:
|
|
|
|
|
|
|
|
|
|||
|
Bank borrowings (terms less than 1 year)
|
195
|
|
|
—
|
|
|
195
|
|
|||
|
Obligations for equity affiliates
2
:
|
|
|
|
|
|
|
|
|
|||
|
Bank borrowings (terms up to 2 years)
|
13
|
|
|
6
|
|
|
19
|
|
|||
|
Revenue bonds (terms up to 4 years)
|
—
|
|
|
23
|
|
|
23
|
|
|||
|
Total obligations for customers, suppliers, other affiliated
companies, and equity affiliates
|
350
|
|
|
200
|
|
|
550
|
|
|||
|
Obligations for divested subsidiaries
3
:
|
|
|
|
|
|
|
|
|
|||
|
Conoco (terms up to 15 years)
|
—
|
|
|
16
|
|
|
16
|
|
|||
|
Total obligations for divested subsidiaries
|
—
|
|
|
16
|
|
|
16
|
|
|||
|
Total
|
$
|
350
|
|
|
$
|
216
|
|
|
$
|
566
|
|
|
1
|
Existing guarantees for customers and suppliers arose as part of contractual agreements.
|
|
2
|
Existing guarantees for equity affiliates and other affiliated companies arose for liquidity needs in normal operations.
|
|
Consolidated Changes
in Equity for the
Three Months Ended
September 30, 2011
|
|
Total
|
|
Comprehensive
Income
|
|
Preferred
Stock
|
|
Common
Stock
|
|
Additional
Paid-in
Capital
|
|
Reinvested
Earnings
|
|
Accumulated
Other
Comprehensive
Loss
|
|
Treasury
Stock
|
|
Noncontrolling
Interests
|
||||||||||||||||||
|
Beginning balance
|
|
$
|
12,502
|
|
|
—
|
|
|
$
|
237
|
|
|
$
|
305
|
|
|
$
|
9,978
|
|
|
$
|
13,683
|
|
|
$
|
(5,453
|
)
|
|
$
|
(6,727
|
)
|
|
$
|
479
|
|
|
|
Comprehensive income:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
|
Sale of a majority interest in a consolidated subsidiary
|
|
(3
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(3
|
)
|
||||||||||||||||
|
Net income
|
|
460
|
|
|
$
|
460
|
|
|
|
|
|
|
|
|
|
|
|
452
|
|
|
|
|
|
|
|
|
8
|
|
||||||||
|
Other comprehensive income (loss), net of tax:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
|
Cumulative translation adjustment
|
|
(348
|
)
|
|
(348
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(348
|
)
|
|
|
|
|
|
|
|||||||||
|
Net revaluation and clearance of cash flow hedges to earnings
|
|
22
|
|
|
22
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
24
|
|
|
|
|
|
(2
|
)
|
|||||||||
|
Pension benefit plans
|
|
103
|
|
|
103
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
103
|
|
|
|
|
|
|
|
|||||||||
|
Other benefit plans
|
|
(10
|
)
|
|
(10
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(10
|
)
|
|
|
|
|
|
|
|||||||||
|
Other comprehensive income (loss), net of tax:
|
|
(233
|
)
|
|
(233
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
|
Comprehensive income
|
|
227
|
|
|
$
|
227
|
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Common dividends
|
|
(384
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(382
|
)
|
|
|
|
|
|
|
|
(2
|
)
|
|||||||||
|
Preferred dividends
|
|
(3
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(3
|
)
|
|
|
|
|
|
|
|
|
|
|||||||||
|
Common stock issued - compensation plans
|
|
85
|
|
|
|
|
|
|
|
|
|
|
85
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
Common stock repurchased
|
|
(400
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(400
|
)
|
|
|
||||||||||||||||
|
Common stock retired
|
|
—
|
|
|
|
|
|
|
(2
|
)
|
|
(80
|
)
|
|
(318
|
)
|
|
|
|
400
|
|
|
|
|||||||||||||
|
Total Equity as of September 30, 2011
|
|
$
|
12,024
|
|
|
|
|
|
$
|
237
|
|
|
$
|
303
|
|
|
$
|
9,983
|
|
|
$
|
13,432
|
|
|
$
|
(5,684
|
)
|
|
$
|
(6,727
|
)
|
|
$
|
480
|
|
|
|
Consolidated Changes
in Equity for the
Three Months Ended
September 30, 2010
|
|
Total
|
|
Comprehensive
Income
|
|
Preferred
Stock
|
|
Common
Stock
|
|
Additional
Paid-in
Capital
|
|
Reinvested
Earnings
|
|
Accumulated
Other
Comprehensive
Loss
|
|
Treasury
Stock
|
|
Noncontrolling
Interests
|
|||||||||||||||||||
|
Beginning balance
|
|
$
|
9,276
|
|
|
|
|
|
$
|
237
|
|
|
$
|
298
|
|
|
$
|
8,569
|
|
|
$
|
12,245
|
|
|
$
|
(5,796
|
)
|
|
$
|
(6,727
|
)
|
|
$
|
450
|
|
||
|
Comprehensive income:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
Net income
|
|
369
|
|
|
$
|
369
|
|
|
|
|
|
|
|
|
|
|
|
367
|
|
|
|
|
|
|
|
|
2
|
|
|||||||||
|
Other comprehensive income (loss), net of tax:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
Cumulative translation adjustment
|
|
108
|
|
|
108
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
106
|
|
|
|
|
|
2
|
|
||||||||||
|
Net revaluation and clearance of cash flow hedges to earnings
|
|
1
|
|
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1
|
|
|
|
|
|
|
|
||||||||||
|
Pension benefit plans
|
|
86
|
|
|
86
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
86
|
|
|
|
|
|
|
|
||||||||||
|
Other benefit plans
|
|
(8
|
)
|
|
(8
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(8
|
)
|
|
|
|
|
|
|
||||||||||
|
Net unrealized gain on securities
|
|
1
|
|
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1
|
|
|
|
|
|
|
|
||||||||||
|
Other comprehensive income (loss), net of tax:
|
|
188
|
|
|
188
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
Comprehensive income
|
|
557
|
|
|
$
|
557
|
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Common dividends
|
|
(374
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(374
|
)
|
|
|
|
|
|
|
|
|
|
||||||||||
|
Preferred dividends
|
|
(3
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(3
|
)
|
|
|
|
|
|
|
|
|
|
||||||||||
|
Common stock issued - compensation plans
|
|
195
|
|
|
|
|
|
|
|
|
1
|
|
|
194
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
Total Equity as of
September 30, 2010
|
|
$
|
9,651
|
|
|
|
|
|
$
|
237
|
|
|
$
|
299
|
|
|
$
|
8,763
|
|
|
$
|
12,235
|
|
|
$
|
(5,610
|
)
|
|
$
|
(6,727
|
)
|
|
$
|
454
|
|
||
|
1
|
Includes comprehensive income attributable to noncontrolling interests of
$6
and
$4
for the three months ended
September 30, 2011
and
2010
, respectively.
|
|
Consolidated Changes
in Equity for the
Nine Months Ended
September 30, 2011
|
|
Total
|
|
Comprehensive
Income
|
|
Preferred
Stock
|
|
Common
Stock
|
|
Additional
Paid-in
Capital
|
|
Reinvested
Earnings
|
|
Accumulated
Other
Comprehensive
Loss
|
|
Treasury
Stock
|
|
Noncontrolling
Interests
|
||||||||||||||||||
|
Beginning balance
|
|
$
|
9,743
|
|
|
|
|
|
$
|
237
|
|
|
$
|
301
|
|
|
$
|
9,227
|
|
|
$
|
12,030
|
|
|
$
|
(5,790
|
)
|
|
$
|
(6,727
|
)
|
|
$
|
465
|
|
|
|
Comprehensive income:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
|
Sale of a majority interest in a consolidated subsidiary
|
|
(3
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(3
|
)
|
||||||||||||||||
|
Net income
|
|
3,133
|
|
|
$
|
3,133
|
|
|
|
|
|
|
|
|
|
|
3,101
|
|
|
|
|
|
|
|
|
32
|
|
|||||||||
|
Other comprehensive income (loss), net of tax:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
|
Cumulative translation adjustment
|
|
(231
|
)
|
|
(231
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(231
|
)
|
|
|
|
|
|
|
|||||||||
|
Net revaluation and clearance of cash flow hedges to earnings
|
|
56
|
|
|
56
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
61
|
|
|
|
|
|
(5
|
)
|
|||||||||
|
Pension benefit plans
|
|
305
|
|
|
305
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
305
|
|
|
|
|
|
|
|
|||||||||
|
Other benefit plans
|
|
(29
|
)
|
|
(29
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(29
|
)
|
|
|
|
|
|
|
|||||||||
|
Other comprehensive income (loss), net of tax:
|
|
101
|
|
|
101
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
|
Comprehensive income
|
|
3,234
|
|
|
$
|
3,234
|
|
2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Common dividends
|
|
(1,159
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1,150
|
)
|
|
|
|
|
|
|
|
(9
|
)
|
|||||||||
|
Preferred dividends
|
|
(8
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(8
|
)
|
|
|
|
|
|
|
|
|
|
|||||||||
|
Common stock issued - compensation plans
|
|
889
|
|
|
|
|
|
|
|
|
6
|
|
|
883
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
|
Common stock repurchased
|
|
(672
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(672
|
)
|
|
|
||||||||||||||||
|
Common stock retired
|
|
—
|
|
|
|
|
|
|
(4
|
)
|
|
(127
|
)
|
|
(541
|
)
|
|
|
|
672
|
|
|
|
|||||||||||||
|
Total Equity as of
September 30, 2011
|
|
$
|
12,024
|
|
|
|
|
|
$
|
237
|
|
|
$
|
303
|
|
|
$
|
9,983
|
|
|
$
|
13,432
|
|
|
$
|
(5,684
|
)
|
|
$
|
(6,727
|
)
|
|
$
|
480
|
|
|
|
Consolidated Changes
in Equity for the
Nine Months Ended
September 30, 2010
|
|
Total
|
|
Comprehensive
Income
|
|
Preferred
Stock
|
|
Common
Stock
|
|
Additional
Paid-in
Capital
|
|
Reinvested
Earnings
|
|
Accumulated
Other
Comprehensive
Loss
|
|
Treasury
Stock
|
|
Noncontrolling
Interests
|
|||||||||||||||||||
|
Beginning balance
|
|
$
|
7,651
|
|
|
|
|
|
$
|
237
|
|
|
$
|
297
|
|
|
$
|
8,469
|
|
|
$
|
10,710
|
|
|
$
|
(5,771
|
)
|
|
$
|
(6,727
|
)
|
|
$
|
436
|
|
||
|
Comprehensive income:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
|
Net income
|
|
2,674
|
|
|
$
|
2,674
|
|
|
|
|
|
|
|
|
|
|
|
2,655
|
|
|
|
|
|
|
|
|
19
|
|
|||||||||
|
Other comprehensive income (loss), net of tax:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
Cumulative translation adjustment
|
|
(43
|
)
|
|
(43
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
(44
|
)
|
|
|
|
|
1
|
|
|||||||||||
|
Net revaluation and clearance of cash flow hedges to earnings
|
|
(11
|
)
|
|
(11
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(11
|
)
|
|
|
|
|
|
|
||||||||||
|
Pension benefit plans
|
|
253
|
|
|
253
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
253
|
|
|
|
|
|
|
|
||||||||||
|
Other benefit plans
|
|
(35
|
)
|
|
(35
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(35
|
)
|
|
|
|
|
|
|
||||||||||
|
Net unrealized loss on securities
|
|
(2
|
)
|
|
(2
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(2
|
)
|
|
|
|
|
|
|
||||||||||
|
Other comprehensive income (loss), net of tax:
|
|
162
|
|
|
162
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
Comprehensive income
|
|
2,836
|
|
|
$
|
2,836
|
|
2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Common dividends
|
|
(1,124
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1,122
|
)
|
|
|
|
|
|
|
|
(2
|
)
|
||||||||||
|
Preferred dividends
|
|
(8
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(8
|
)
|
|
|
|
|
|
|
|
|
|
||||||||||
|
Common stock issued - compensation plans
|
|
296
|
|
|
|
|
|
|
|
|
2
|
|
|
294
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
Total Equity as of
September 30, 2010
|
|
$
|
9,651
|
|
|
|
|
|
$
|
237
|
|
|
$
|
299
|
|
|
$
|
8,763
|
|
|
$
|
12,235
|
|
|
$
|
(5,610
|
)
|
|
$
|
(6,727
|
)
|
|
$
|
454
|
|
||
|
2
|
Includes comprehensive income attributable to noncontrolling interests of
$27
and
$20
for the nine months ended
September 30, 2011
and
2010
, respectively.
|
|
|
Three Months Ended
|
|
Three Months Ended
|
||||||||||||||||||||
|
|
September 30, 2011
|
|
September 30, 2010
|
||||||||||||||||||||
|
|
Pre-tax
|
|
Tax
|
|
After-Tax
|
|
Pre-tax
|
|
Tax
|
|
After-Tax
|
||||||||||||
|
Beginning balance
|
$
|
11
|
|
|
$
|
(5
|
)
|
|
$
|
6
|
|
|
$
|
(119
|
)
|
|
$
|
42
|
|
|
$
|
(77
|
)
|
|
Additions and revaluations of derivatives designated as cash flow hedges
|
13
|
|
|
(5
|
)
|
|
8
|
|
|
(18
|
)
|
|
6
|
|
|
(12
|
)
|
||||||
|
Clearance of hedge results to earnings
|
25
|
|
|
(9
|
)
|
|
16
|
|
|
20
|
|
|
(7
|
)
|
|
13
|
|
||||||
|
Ending balance
|
$
|
49
|
|
|
$
|
(19
|
)
|
|
$
|
30
|
|
|
$
|
(117
|
)
|
|
$
|
41
|
|
|
$
|
(76
|
)
|
|
|
Nine Months Ended
|
|
Nine Months Ended
|
||||||||||||||||||||
|
|
September 30, 2011
|
|
September 30, 2010
|
||||||||||||||||||||
|
|
Pre-tax
|
|
Tax
|
|
After-Tax
|
|
Pre-tax
|
|
Tax
|
|
After-Tax
|
||||||||||||
|
Beginning balance
|
$
|
(47
|
)
|
|
$
|
16
|
|
|
$
|
(31
|
)
|
|
$
|
(101
|
)
|
|
$
|
36
|
|
|
$
|
(65
|
)
|
|
Additions and revaluations of derivatives designated as cash flow hedges
|
19
|
|
|
(6
|
)
|
|
13
|
|
|
(80
|
)
|
|
29
|
|
|
(51
|
)
|
||||||
|
Clearance of hedge results to earnings
|
77
|
|
|
(29
|
)
|
|
48
|
|
|
64
|
|
|
(24
|
)
|
|
40
|
|
||||||
|
Ending balance
|
$
|
49
|
|
|
$
|
(19
|
)
|
|
$
|
30
|
|
|
$
|
(117
|
)
|
|
$
|
41
|
|
|
$
|
(76
|
)
|
|
|
Asset Derivatives
|
|
Liability Derivatives
|
|
||||||||||||||||
|
|
September 30, 2011
|
|
December 31, 2010
|
|
September 30, 2011
|
|
December 31, 2010
|
|
||||||||||||
|
Derivatives designated as hedging instruments
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Interest rate swaps
|
$
|
71
|
|
2
|
|
$
|
40
|
|
2
|
|
$
|
—
|
|
|
$
|
—
|
|
|
||
|
Foreign currency contracts
|
35
|
|
1
|
|
20
|
|
1
|
|
4
|
|
4
|
|
3
|
|
4
|
|
||||
|
Energy feedstocks
|
—
|
|
|
3
|
|
1
|
|
24
|
|
4
|
|
75
|
|
4
|
|
|||||
|
Total derivatives designated as hedging instruments
|
$
|
106
|
|
|
$
|
63
|
|
|
$
|
28
|
|
|
$
|
78
|
|
|
||||
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
Derivatives not designated as hedging instruments
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Foreign currency contracts
|
$
|
170
|
|
1
|
|
$
|
90
|
|
1
|
|
$
|
72
|
|
4
|
|
$
|
54
|
|
4
|
|
|
Cross-currency swaps
|
25
|
|
3
|
|
—
|
|
|
—
|
|
|
—
|
|
|
|||||||
|
Agricultural feedstocks
|
—
|
|
|
—
|
|
|
1
|
|
4
|
|
—
|
|
|
|||||||
|
Total derivatives not designated as hedging instruments
|
$
|
195
|
|
|
$
|
90
|
|
|
$
|
73
|
|
|
$
|
54
|
|
|
||||
|
Total derivatives
|
$
|
301
|
|
|
$
|
153
|
|
|
$
|
101
|
|
|
$
|
132
|
|
|
||||
|
|
|
Amount of Gain or
(Loss) Recognized in
Income of Derivative
|
|
Amount of Gain or
(Loss) Recognized in
Income on Hedged Item
|
|
Amount of Gain or
(Loss) Recognized in
Income of Derivative
|
|
Amount of Gain or
(Loss) Recognized in
Income on Hedged Item
|
|
||||||||||||
|
Derivatives in Fair Value
Hedging Relationships
|
|
Three Months Ended
September 30, 2011
|
|
Three Months Ended
September 30, 2011
|
|
Three Months Ended
September 30, 2010
|
|
Three Months Ended
September 30, 2010
|
|
||||||||||||
|
Interest rate swaps
|
|
$
|
22
|
|
1
|
|
$
|
(22
|
)
|
1
|
|
$
|
28
|
|
1
|
|
$
|
(28
|
)
|
1
|
|
|
Total
|
|
$
|
22
|
|
|
$
|
(22
|
)
|
|
$
|
28
|
|
|
$
|
(28
|
)
|
|
||||
|
Derivatives in Fair Value
Hedging Relationships
|
|
Nine Months Ended
September 30, 2011
|
|
Nine Months Ended
September 30, 2011
|
|
Nine Months Ended
September 30, 2010
|
|
Nine Months Ended September 30, 2010
|
|
||||||||||||
|
Interest rate swaps
|
|
$
|
31
|
|
1
|
|
$
|
(31
|
)
|
1
|
|
$
|
67
|
|
1
|
|
$
|
(67
|
)
|
1
|
|
|
Total
|
|
$
|
31
|
|
|
$
|
(31
|
)
|
|
$
|
67
|
|
|
$
|
(67
|
)
|
|
||||
|
|
|
Amount of Gain or
(Loss) Recognized in
OCI
1
on Derivative
(Effective Portion)
|
|
Amount of Gain or
(Loss) Reclassified from
Accumulated OCI
1
into
Income (Effective
Portion)
|
|
Amount of Gain or
(Loss) Recognized in
Income on Derivative
(Ineffective Portion and
Amount Excluded from
Effectiveness Testing)
|
|
||||||||
|
Derivatives in Cash Flow
Hedging Relationships
|
|
Three Months Ended
September 30, 2011
|
|
Three Months Ended
September 30, 2011
|
|
Three Months Ended
September 30, 2011
|
|
||||||||
|
Foreign currency contracts
|
|
$
|
15
|
|
|
$
|
(7
|
)
|
2
|
|
$
|
—
|
|
|
|
|
Agricultural feedstocks
|
|
5
|
|
|
—
|
|
|
1
|
|
3
|
|
||||
|
Energy feedstocks
|
|
(7
|
)
|
|
(18
|
)
|
3
|
|
—
|
|
|
||||
|
Total
|
|
$
|
13
|
|
|
$
|
(25
|
)
|
|
$
|
1
|
|
|
||
|
|
Nine Months Ended
September 30, 2011
|
|
Nine Months Ended
September 30, 2011
|
|
Nine Months Ended
September 30, 2011
|
|
||||||||
|
Foreign currency contracts
|
$
|
(5
|
)
|
|
$
|
(19
|
)
|
2
|
|
$
|
—
|
|
|
|
|
Agricultural feedstocks
|
33
|
|
|
(2
|
)
|
3
|
|
6
|
|
3
|
|
|||
|
Energy feedstocks
|
(9
|
)
|
|
(56
|
)
|
3
|
|
—
|
|
|
||||
|
Total
|
$
|
19
|
|
|
$
|
(77
|
)
|
|
$
|
6
|
|
|
||
|
|
|
Amount of Gain or
(Loss) Recognized in
OCI
1
on Derivative
(Effective Portion)
|
|
Amount of Gain or
(Loss) Reclassified from
Accumulated OCI
1
into
Income (Effective
Portion)
|
|
Amount of Gain or
(Loss) Recognized in
Income on Derivative
(Ineffective Portion and
Amount Excluded from
Effectiveness Testing)
|
|
||||||||
|
Derivatives in Cash Flow
Hedging Relationships
|
|
Three Months Ended
September 30, 2010
|
|
Three Months Ended
September 30, 2010
|
|
Three Months Ended
September 30, 2010
|
|
||||||||
|
Treasury rate contracts
|
|
$
|
(3
|
)
|
|
$
|
—
|
|
|
$
|
—
|
|
|
||
|
Foreign currency contracts
|
|
(12
|
)
|
|
(3
|
)
|
2
|
|
—
|
|
|
||||
|
Agricultural feedstocks
|
|
11
|
|
|
—
|
|
|
2
|
|
3
|
|
||||
|
Energy feedstocks
|
|
(14
|
)
|
|
(17
|
)
|
3
|
|
—
|
|
|
||||
|
Total
|
|
$
|
(18
|
)
|
|
$
|
(20
|
)
|
|
$
|
2
|
|
|
||
|
|
Nine Months Ended
September 30, 2010
|
|
Nine Months Ended
September 30, 2010
|
|
Nine Months Ended
September 30, 2010
|
|
||||||||
|
Treasury rate contracts
|
$
|
(3
|
)
|
|
$
|
—
|
|
|
$
|
—
|
|
|
||
|
Foreign currency contracts
|
(2
|
)
|
|
9
|
|
2
|
|
—
|
|
|
||||
|
Agricultural feedstocks
|
(31
|
)
|
|
(21
|
)
|
3
|
|
(1
|
)
|
3
|
|
|||
|
Energy feedstocks
|
(44
|
)
|
|
(52
|
)
|
3
|
|
—
|
|
|
||||
|
Total
|
$
|
(80
|
)
|
|
$
|
(64
|
)
|
|
$
|
(1
|
)
|
|
||
|
|
|
Amount of Gain or (Loss) Recognized in Income on
Derivative
|
|
Amount of Gain or (Loss) Recognized in Income on
Derivative
|
|
|||||||||||||||
|
Derivatives Not Designated in Hedging Instruments
|
|
Three Months Ended September 30, 2011
|
|
Three Months Ended September 30, 2010
|
|
Nine Months Ended September 30, 2011
|
|
Nine Months Ended September 30, 2010
|
|
|||||||||||
|
Foreign currency contracts
|
|
$
|
180
|
|
1
|
|
$
|
(443
|
)
|
1
|
|
$
|
(227
|
)
|
1
|
$
|
100
|
|
1
|
|
|
Cross-currency swaps
|
|
42
|
|
1
|
|
—
|
|
|
25
|
|
1
|
—
|
|
|
||||||
|
Agricultural feedstocks
|
|
(6
|
)
|
2
|
|
(20
|
)
|
2
|
|
6
|
|
2
|
5
|
|
2
|
|
||||
|
Energy feedstocks
|
|
(1
|
)
|
2
|
|
—
|
|
|
(2
|
)
|
2
|
—
|
|
|
||||||
|
Interest rate swaps
|
|
—
|
|
|
—
|
|
|
(1
|
)
|
2
|
—
|
|
|
|||||||
|
Total
|
|
$
|
215
|
|
|
$
|
(463
|
)
|
|
(199
|
)
|
|
105
|
|
|
|||||
|
|
Three Months Ended
|
|
Nine Months Ended
|
||||||||||||
|
|
September 30,
|
|
September 30,
|
||||||||||||
|
|
2011
|
|
2010
|
|
2011
|
|
2010
|
||||||||
|
Service cost
|
$
|
62
|
|
|
$
|
53
|
|
|
$
|
182
|
|
|
$
|
154
|
|
|
Interest cost
|
316
|
|
|
316
|
|
|
940
|
|
|
946
|
|
||||
|
Expected return on plan assets
|
(371
|
)
|
|
(360
|
)
|
|
(1,105
|
)
|
|
(1,076
|
)
|
||||
|
Amortization of unrecognized loss
|
153
|
|
|
126
|
|
|
459
|
|
|
379
|
|
||||
|
Amortization of prior service cost
|
4
|
|
|
4
|
|
|
12
|
|
|
12
|
|
||||
|
Net periodic benefit cost
|
$
|
164
|
|
|
$
|
139
|
|
|
$
|
488
|
|
|
$
|
415
|
|
|
|
Three Months Ended
|
|
Nine Months Ended
|
||||||||||||
|
|
September 30,
|
|
September 30,
|
||||||||||||
|
|
2011
|
|
2010
|
|
2011
|
|
2010
|
||||||||
|
Service cost
|
$
|
8
|
|
|
$
|
7
|
|
|
$
|
25
|
|
|
$
|
21
|
|
|
Interest cost
|
53
|
|
|
60
|
|
|
159
|
|
|
179
|
|
||||
|
Amortization of unrecognized loss
|
15
|
|
|
15
|
|
|
45
|
|
|
44
|
|
||||
|
Amortization of prior service benefit
|
(30
|
)
|
|
(27
|
)
|
|
(91
|
)
|
|
(80
|
)
|
||||
|
Net periodic benefit cost
|
$
|
46
|
|
|
$
|
55
|
|
|
$
|
138
|
|
|
$
|
164
|
|
|
Three Months Ended
September 30,
|
|
Agriculture
2
|
|
Electronics &
Communications
|
|
Industrial Biosciences
3
|
|
Nutrition & Health
4
|
|
Performance
Chemicals
|
|
Performance
Coatings
|
|
Performance
Materials
|
|
Safety &
Protection
|
|
Pharm-aceuticals
|
|
Other
|
|
Total
1
|
||||||||||||||||||||||
|
2011
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
|
Segment sales
|
|
$
|
1,368
|
|
|
$
|
841
|
|
|
$
|
293
|
|
|
$
|
844
|
|
|
$
|
2,142
|
|
|
$
|
1,100
|
|
|
$
|
1,745
|
|
|
$
|
1,001
|
|
|
$
|
—
|
|
|
$
|
2
|
|
|
$
|
9,336
|
|
|
Transfers
|
|
(1
|
)
|
|
(4
|
)
|
|
(4
|
)
|
|
—
|
|
|
(58
|
)
|
|
—
|
|
|
(27
|
)
|
|
(4
|
)
|
|
—
|
|
|
—
|
|
|
(98
|
)
|
|||||||||||
|
Net sales
|
|
1,367
|
|
|
837
|
|
|
289
|
|
|
844
|
|
|
2,084
|
|
|
1,100
|
|
|
1,718
|
|
|
997
|
|
|
—
|
|
|
2
|
|
|
9,238
|
|
|||||||||||
|
PTOI
|
|
(194
|
)
|
5,6
|
99
|
|
|
(27
|
)
|
7,8
|
(34
|
)
|
7,8
|
593
|
|
|
72
|
|
|
231
|
|
|
118
|
|
|
70
|
|
|
(78
|
)
|
7
|
850
|
|
|||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||
|
2010
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
|
Segment sales
|
|
$
|
967
|
|
|
$
|
703
|
|
|
$
|
—
|
|
|
$
|
304
|
|
|
$
|
1,675
|
|
|
$
|
937
|
|
|
$
|
1,578
|
|
|
$
|
871
|
|
|
$
|
—
|
|
|
$
|
49
|
|
|
$
|
7,084
|
|
|
Transfers
|
|
—
|
|
|
(4
|
)
|
|
—
|
|
|
—
|
|
|
(59
|
)
|
|
—
|
|
|
(17
|
)
|
|
(3
|
)
|
|
—
|
|
|
—
|
|
|
(83
|
)
|
|||||||||||
|
Net sales
|
|
967
|
|
|
699
|
|
|
—
|
|
|
304
|
|
|
1,616
|
|
|
937
|
|
|
1,561
|
|
|
868
|
|
|
—
|
|
|
49
|
|
|
7,001
|
|
|||||||||||
|
PTOI
|
|
(191
|
)
|
|
126
|
|
|
—
|
|
|
10
|
|
|
292
|
|
|
64
|
|
|
281
|
|
|
134
|
|
|
111
|
|
|
(64
|
)
|
|
763
|
|
|||||||||||
|
Nine Months Ended
September 30,
|
|
Agriculture
2
|
|
Electronics &
Communications
|
|
Industrial Biosciences
3
|
|
Nutrition & Health
4
|
|
Performance
Chemicals
|
|
Performance
Coatings
|
|
Performance
Materials
|
|
Safety &
Protection
|
|
Pharm-aceuticals
|
|
Other
|
|
Total
1
|
||||||||||||||||||||||
|
2011
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
|
Segment sales
|
|
$
|
7,869
|
|
|
$
|
2,543
|
|
|
$
|
416
|
|
|
$
|
1,654
|
|
|
$
|
5,934
|
|
|
$
|
3,198
|
|
|
$
|
5,197
|
|
|
$
|
2,991
|
|
|
$
|
—
|
|
|
$
|
39
|
|
|
$
|
29,841
|
|
|
Transfers
|
|
(1
|
)
|
|
(14
|
)
|
|
(5
|
)
|
|
—
|
|
|
(194
|
)
|
|
—
|
|
|
(81
|
)
|
|
(10
|
)
|
|
—
|
|
|
—
|
|
|
(305
|
)
|
|||||||||||
|
Net sales
|
|
7,868
|
|
|
2,529
|
|
|
411
|
|
|
1,654
|
|
|
5,740
|
|
|
3,198
|
|
|
5,116
|
|
|
2,981
|
|
|
—
|
|
|
39
|
|
|
29,536
|
|
|||||||||||
|
PTOI
|
|
1,743
|
|
5,6
|
313
|
|
|
(34
|
)
|
7,9
|
(4
|
)
|
7,9
|
1,490
|
|
|
210
|
|
|
773
|
|
|
406
|
|
|
200
|
|
|
(179
|
)
|
7
|
4,918
|
|
|||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||
|
2010
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
|
Segment sales
|
|
$
|
6,641
|
|
|
$
|
1,991
|
|
|
$
|
—
|
|
|
$
|
902
|
|
|
$
|
4,658
|
|
|
$
|
2,801
|
|
|
$
|
4,688
|
|
|
$
|
2,505
|
|
|
$
|
—
|
|
|
$
|
154
|
|
|
$
|
24,340
|
|
|
Transfers
|
|
(1
|
)
|
|
(13
|
)
|
|
—
|
|
|
—
|
|
|
(162
|
)
|
|
(1
|
)
|
|
(54
|
)
|
|
(8
|
)
|
|
—
|
|
|
—
|
|
|
(239
|
)
|
|||||||||||
|
Net sales
|
|
6,640
|
|
|
1,978
|
|
|
—
|
|
|
902
|
|
|
4,496
|
|
|
2,800
|
|
|
4,634
|
|
|
2,497
|
|
|
—
|
|
|
154
|
|
|
24,101
|
|
|||||||||||
|
PTOI
|
|
1,478
|
|
|
339
|
|
|
—
|
|
|
44
|
|
|
756
|
|
|
184
|
|
|
772
|
|
|
357
|
|
|
402
|
|
|
(111
|
)
|
|
4,221
|
|
|||||||||||
|
|
Three Months Ended
September 30,
|
|
Nine Months Ended
September 30,
|
||||||||||||
|
|
2011
|
|
2010
|
|
2011
|
|
2010
|
||||||||
|
Total segment PTOI
|
$
|
850
|
|
|
$
|
763
|
|
|
$
|
4,918
|
|
|
$
|
4,221
|
|
|
Net exchange losses, including affiliates
|
(6
|
)
|
|
(160
|
)
|
|
(145
|
)
|
|
(25
|
)
|
||||
|
Corporate expenses and net interest
|
(275
|
)
|
|
(273
|
)
|
|
(913
|
)
|
|
(711
|
)
|
||||
|
Income before income taxes
|
$
|
569
|
|
|
$
|
330
|
|
|
$
|
3,860
|
|
|
$
|
3,485
|
|
|
2
|
As of
September 30, 2011
, Agriculture net assets were
$8,058
, an increase of
$3,131
from
$4,927
at
December 31, 2010
. The increase was primarily due to higher trade receivables due to normal seasonality in the sales and cash collections cycle.
|
|
3
|
As of
September 30, 2011
, Industrial Biosciences net assets were
$2,596
compared to
$0
at December 31, 2010, due to the Danisco acquisition.
|
|
4
|
As of
September 30, 2011
, Nutrition & Health net assets were
$6,497
, an increase of
$5,547
from
$950
at December 31,
2010. The increase was primarily due to the Danisco acquisition.
|
|
5
|
Included a
$(50)
charge recorded in research and development expense in connection with a milestone payment associated with a Pioneer licensing agreement. Since this milestone was reached before regulatory approval was secured by Pioneer, it was charged to research and development expense.
|
|
6
|
Included a
$(75)
charge recorded in cost of goods sold and other operating charges associated with the company's process to fairly resolve claims associated with the use of Imprelis
®
. See Note 11 for additional information.
|
|
7
|
Included a
$(36)
restructuring charge impacting the following segments: Industrial Biosciences -
$(8)
; Nutrition & Health -
$(10)
; and Other -
$(18)
. See Note 4 for additional information.
|
|
8
|
Included a
$(132)
charge for the fair value step-up of inventories that were acquired as part of the Danisco transaction and sold in the third quarter 2011, which impacted the segments as follows: Industrial Biosciences -
$(53)
and Nutrition & Health -
$(79)
.
|
|
9
|
Included second and third quarter 2011 charges totaling
$(182)
for transaction related costs and the fair value step-up of inventories that were acquired as par
t of the Danisco transaction, which impacted the segments as follows: Industrial Biosciences -
$(70)
and Nutrition &
Health -
$(112)
.
|
|
Item 2.
|
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
|
|
•
|
Fluctuations in energy and raw material prices;
|
|
•
|
Failure to develop and market new products and optimally manage product life cycles;
|
|
•
|
Outcome of significant litigation and environmental matters, including those related to divested businesses;
|
|
•
|
Failure to appropriately manage process safety and product stewardship issues;
|
|
•
|
Effect of changes in tax, environmental and other laws and regulations or political conditions in the United States of America (U.S.) and other countries in which the company operates;
|
|
•
|
Conditions in the global economy and global capital markets, including economic factors, such as inflation, deflation and fluctuations in currency exchange rates, interest rates and commodity prices, as well as regulatory requirements;
|
|
•
|
Impact of business disruptions, including supply disruptions, and security threats, regardless of cause, including acts of sabotage, terrorism or war, weather events and natural disasters;
|
|
•
|
Inability to protect and enforce the company's intellectual property rights; and
|
|
•
|
Successful integration of acquired businesses and completion of divestitures of underperforming or non-strategic assets or businesses.
|
|
|
Three Months Ended
September 30, 2011
|
|
|
Percent Change Due to:
|
||||||||||||||
|
|
Net Sales
($ Billions)
|
|
Percent
Change vs.
2010
|
|
Local
Price
|
|
Currency
Effect
|
|
Volume
|
|
Portfolio
|
|||||||
|
Worldwide
|
$
|
9.2
|
|
|
32
|
|
|
15
|
|
|
4
|
|
|
1
|
|
|
12
|
|
|
U.S. & Canada
|
2.9
|
|
|
23
|
|
|
12
|
|
|
—
|
|
|
(1
|
)
|
|
12
|
|
|
|
Europe, Middle East & Africa (EMEA)
|
2.4
|
|
|
40
|
|
|
14
|
|
|
11
|
|
|
(2
|
)
|
|
17
|
|
|
|
Asia Pacific
|
2.4
|
|
|
29
|
|
|
18
|
|
|
4
|
|
|
(1
|
)
|
|
8
|
|
|
|
Latin America
|
1.5
|
|
|
43
|
|
|
16
|
|
|
3
|
|
|
17
|
|
|
7
|
|
|
|
|
Nine Months Ended
September 30, 2011
|
|
|
Percent Change Due to:
|
||||||||||||||
|
|
Net Sales
($ Billions)
|
|
Percent
Change vs.
2010
|
|
Local
Price
|
|
Currency
Effect
|
|
Volume
|
|
Portfolio
|
|||||||
|
Worldwide
|
$
|
29.5
|
|
|
23
|
|
|
11
|
|
|
3
|
|
|
4
|
|
|
5
|
|
|
U.S. & Canada
|
11.6
|
|
|
16
|
|
|
9
|
|
|
—
|
|
|
1
|
|
|
6
|
|
|
|
EMEA
|
7.7
|
|
|
24
|
|
|
9
|
|
|
5
|
|
|
4
|
|
|
6
|
|
|
|
Asia Pacific
|
6.7
|
|
|
28
|
|
|
16
|
|
|
3
|
|
|
5
|
|
|
4
|
|
|
|
Latin America
|
3.5
|
|
|
35
|
|
|
14
|
|
|
3
|
|
|
15
|
|
|
3
|
|
|
|
|
Three Months Ended
|
|
|
|
|
|
|
||||||||
|
|
September 30, 2011
|
|
Percentage Change Due to:
|
||||||||||||
|
|
Segment
Sales
1
($ Billions)
|
|
Percent
Change vs.
2010
|
|
Selling
Price
|
|
Volume
|
|
Portfolio
and Other
|
||||||
|
Agriculture
|
$
|
1.4
|
|
|
41
|
|
|
15
|
|
|
26
|
|
|
—
|
|
|
Electronics & Communications
|
0.8
|
|
|
20
|
|
|
28
|
|
|
(8
|
)
|
|
—
|
|
|
|
Industrial Biosciences
|
0.3
|
|
|
nm
|
|
|
nm
|
|
|
nm
|
|
|
nm
|
|
|
|
Nutrition & Health
|
0.8
|
|
|
178
|
|
|
6
|
|
|
4
|
|
|
168
|
|
|
|
Performance Chemicals
|
2.1
|
|
|
28
|
|
|
29
|
|
|
(1
|
)
|
|
—
|
|
|
|
Performance Coatings
|
1.1
|
|
|
17
|
|
|
13
|
|
|
4
|
|
|
—
|
|
|
|
Performance Materials
|
1.7
|
|
|
11
|
|
|
18
|
|
|
(7
|
)
|
|
—
|
|
|
|
Safety & Protection
|
1.0
|
|
|
15
|
|
|
8
|
|
|
—
|
|
|
7
|
|
|
|
|
Nine Months Ended
|
|
|
|
|
|
|
||||||||
|
|
September 30, 2011
|
|
Percentage Change Due to:
|
||||||||||||
|
|
Segment
Sales
1
($ Billions)
|
|
Percent
Change vs.
2010
|
|
Selling
Price
|
|
Volume
|
|
Portfolio
and Other
|
||||||
|
Agriculture
|
$
|
7.9
|
|
|
18
|
|
|
6
|
|
|
11
|
|
|
1
|
|
|
Electronics & Communications
|
2.5
|
|
|
28
|
|
|
25
|
|
|
3
|
|
|
—
|
|
|
|
Industrial Biosciences
|
0.4
|
|
|
nm
|
|
|
nm
|
|
|
nm
|
|
|
nm
|
|
|
|
Nutrition & Health
|
1.7
|
|
|
83
|
|
|
5
|
|
|
2
|
|
|
76
|
|
|
|
Performance Chemicals
|
5.9
|
|
|
27
|
|
|
26
|
|
|
1
|
|
|
—
|
|
|
|
Performance Coatings
|
3.2
|
|
|
14
|
|
|
11
|
|
|
3
|
|
|
—
|
|
|
|
Performance Materials
|
5.2
|
|
|
11
|
|
|
13
|
|
|
(1
|
)
|
|
(1
|
)
|
|
|
Safety & Protection
|
3.0
|
|
|
19
|
|
|
5
|
|
|
7
|
|
|
7
|
|
|
|
|
Long-term
|
|
Short-term
|
|
Outlook
|
|
Standard & Poor’s
|
A
|
|
A-1
|
|
Stable
|
|
Moody’s Investors Service
|
A2
|
|
P-1
|
|
Stable
|
|
Fitch Ratings
|
A
|
|
F1
|
|
Stable
|
|
|
Nine Months Ended
|
||||||
|
|
September 30,
|
||||||
|
(Dollars in millions)
|
2011
|
|
2010
|
||||
|
Cash provided by operating activities
|
$
|
431
|
|
|
$
|
35
|
|
|
Purchases of property, plant and equipment
|
(1,211
|
)
|
|
(899
|
)
|
||
|
Free cash flow
|
$
|
(780
|
)
|
|
$
|
(864
|
)
|
|
Item 3.
|
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
|
|
Item 1.
|
LEGAL PROCEEDINGS
|
|
Month
|
Total Number of Shares Purchased
|
Average Price
Paid per Share
|
Total Number of
Shares Purchased as Part of Publicly Announced Program
|
Approximate Value
of Shares that May
Yet Be Purchased
Under the Program
(Dollars in millions)
|
||||||
|
September
|
8,836,596
|
|
$
|
45.27
|
|
8,836,596
|
|
$
|
116
|
|
|
Total
|
8,836,596
|
|
|
8,836,596
|
|
|
||||
|
Item 5.
|
OTHER INFORMATION
|
|
Item 6.
|
EXHIBITS
|
|
|
E. I. DU PONT DE NEMOURS AND COMPANY
|
|
|
|
(Registrant)
|
|
|
|
|
|
|
|
Date:
|
October 25, 2011
|
|
|
|
|
|
|
|
|
|
|
By:
|
/s/Nicholas C. Fanandakis
|
|
|
|
|
|
|
|
Nicholas C. Fanandakis
|
|
|
|
Executive Vice President and
|
|
|
|
Chief Financial Officer
|
|
|
|
(As Duly Authorized Officer and
|
|
|
|
Principal Financial and Accounting Officer)
|
|
Exhibit
Number
|
|
Description
|
|
|
|
|
|
3.1
|
|
Company’s Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the company’s Annual Report on Form 10-K for the year ended December 31, 2007).
|
|
|
|
|
|
3.2
|
|
Company’s Bylaws, as last amended effective November 1, 2009 (incorporated by reference to Exhibit 3.2 to the company’s Annual Report on Form 10-K for the year ended December 31, 2009).
|
|
|
|
|
|
4
|
|
The company agrees to provide the Commission, on request, copies of instruments defining the rights of holders of long-term debt of the company and its subsidiaries.
|
|
|
|
|
|
10.1*
|
|
The DuPont Stock Accumulation and Deferred Compensation Plan for Directors, as last amended effective January 1, 2009 (incorporated by reference to Exhibit 10.1 to the company’s Annual Report on Form 10-K for the year ended December 31, 2008).
|
|
|
|
|
|
10.2*
|
|
Company’s Supplemental Retirement Income Plan, as last amended effective June 4, 1996 (incorporated by reference to Exhibit 10.3 to the company’s Annual Report on Form 10-K for the year ended December 31, 2006).
|
|
|
|
|
|
10.3*
|
|
Company’s Pension Restoration Plan, as restated effective July 17, 2006 (incorporated by reference to Exhibit 10.3 to the company’s Quarterly Report on Form 10-Q for the period ended June 30, 2011).
|
|
|
|
|
|
10.4*
|
|
Company’s Rules for Lump Sum Payments, as last amended effective December 20, 2007 (incorporated by reference to Exhibit 10.4 to the company’s Quarterly Report on Form 10-Q for the period ended June 30, 2011).
|
|
|
|
|
|
10.5*
|
|
Company’s Stock Performance Plan, as last amended effective January 25, 2007 (incorporated by reference to Exhibit 10.7 to the company’s Quarterly Report on Form 10-Q for the period ended March 31, 2007).
|
|
|
|
|
|
10.6*
|
|
Company’s Equity and Incentive Plan as amended and restated effective March 2, 2011 and approved by the company’s shareholders on April 27, 2011 (incorporated by reference to pages B1-B15 of the company’s Annual Meeting Proxy Statement dated March 18, 2011).
|
|
|
|
|
|
10.7*
|
|
Form of Award Terms under the company’s Equity and Incentive Plan (incorporated by reference to Exhibit 10.8 to the company’s Quarterly Report on Form 10-Q for the period ended March 31, 2009).
|
|
|
|
|
|
10.8*
|
|
Company’s Retirement Savings Restoration Plan, as last amended effective June 1, 2011 (incorporated by reference to Exhibit 10.8 to the company’s Quarterly Report on Form 10-Q for the period ended June 30, 2011).
|
|
|
|
|
|
10.9*
|
|
Company’s Retirement Income Plan for Directors, as last amended August 1995 (incorporated by reference to Exhibit 10.17 to the company’s Annual Report on Form 10-K for the year ended December 31, 2007).
|
|
|
|
|
|
10.10*
|
|
Company’s Bicentennial Corporate Sharing Plan, adopted by the Board of Directors on December 12, 2001 and effective January 9, 2002 (incorporated by reference to Exhibit 10.19 to the company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2007).
|
|
Exhibit
Number
|
|
Description
|
|
|
|
|
|
10.11*
|
|
Company’s Management Deferred Compensation Plan, adopted on May 2, 2008, as last amended May 12, 2010 (incorporated by reference to Exhibit 10.11 to the company’s Quarterly Report on Form 10-Q for the period ended June 30, 2010).
|
|
|
|
|
|
10.12*
|
|
Supplemental Deferral Terms for Deferred Long Term Incentive Awards and Deferred Variable Compensation Awards (incorporated by reference to Exhibit 10.15 to the company’s Annual Report on Form 10-K for the year ended December 31, 2008).
|
|
|
|
|
|
12
|
|
Computation of Ratio of Earnings to Fixed Charges.
|
|
|
|
|
|
31.1
|
|
Rule 13a-14(a)/15d-14(a) Certification of the company’s Principal Executive Officer.
|
|
|
|
|
|
31.2
|
|
Rule 13a-14(a)/15d-14(a) Certification of the company’s Principal Financial Officer.
|
|
|
|
|
|
32.1
|
|
Section 1350 Certification of the company’s Principal Executive Officer. The information contained in this Exhibit shall not be deemed filed with the Securities and Exchange Commission nor incorporated by reference in any registration statement filed by the registrant under the Securities Act of 1933, as amended.
|
|
|
|
|
|
32.2
|
|
Section 1350 Certification of the company’s Principal Financial Officer. The information contained in this Exhibit shall not be deemed filed with the Securities and Exchange Commission nor incorporated by reference in any registration statement filed by the registrant under the Securities Act of 1933, as amended.
|
|
|
|
|
|
101.INS
|
|
XBRL Instance Document
|
|
|
|
|
|
101.SCH
|
|
XBRL Taxonomy Extension Schema Document
|
|
|
|
|
|
101.CAL
|
|
XBRL Taxonomy Extension Calculation Linkbase Document
|
|
|
|
|
|
101.DEF
|
|
XBRL Taxonomy Extension Definition Linkbase Document
|
|
|
|
|
|
101.LAB
|
|
XBRL Taxonomy Extension Label Linkbase Document
|
|
|
|
|
|
101.PRE
|
|
XBRL Taxonomy Extension Presentation Linkbase Document
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|